Effects of immunoglobulin upon murine myocarditis caused by influenza A virus: superiority of intact type to F(ab')2 type - PubMed (original) (raw)
Effects of immunoglobulin upon murine myocarditis caused by influenza A virus: superiority of intact type to F(ab')2 type
Chiharu Kishimoto et al. J Cardiovasc Pharmacol. 2004 Jan.
Abstract
Influenza viruses play the largest role in the worldwide epidemiology of infectious diseases. Management of some inflammatory disease (eg, Kawasaki disease) with immunoglobulin has been demonstrated to be effective. We examined the effects of intact type and F(ab')2 type of immunoglobulin preparations upon murine influenza A virus myocarditis in mice. In vitro study showed that intact type and F(ab')2 type of immunoglobulin preparations exhibit antiviral activities against many substrains of influenza virus and other cardiotropic viruses. Dose-dependent suppression of an influenza A virus (NWS) was demonstrated by management with both intact immunoglobulin and F(ab')2 fragments of immunoglobulin. The dose inhibiting 50% of plaques was the same between intact type and F(ab')2 type (both 0.0002 mg/dl). Intact immunoglobulin, but not F(ab')2 fragments of immunoglobulin, suppressed serum macrophage inflammatory protein-2 (MIP-2) productions in influenza A virus-infected macrophages in vitro, which is a murine counterpart of interleukin-8. This suppression of MIP-2 production by intact immunoglobulin treatment was blocked by a specific Fc receptor (Fc gamma III/II receptor) antibody pretreatment. Intact immunoglobulin or F(ab')2 fragments of immunoglobulin were administered to virus-inoculated A/J mice intraperitoneally daily, starting simultaneously with virus inoculation (Experiment I) and 2 days after the virus inoculation (Experiment II), until 10 days after virus inoculation. In Experiment I, survival was higher in treated than in control mice; intact type and F(ab')2 type immunoglobulins administration completely suppressed the development of myocarditis. In Experiment II, survival rate was significantly higher and myocarditis was less severe in intact immunoglobulin-treated mice, but not in F(ab')2 fragments-treated mice compared with untreated mice. Serum neutralizing antibody titers in treated mice were significantly higher compared with untreated mice in Experiments I and II. In addition, serum MIP-2 concentrations in intact immunoglobulin-treated mice, but not in F(ab')2 fragments-treated mice, were lower compared with untreated mice in Experiment II. Immunoglobulin therapy suppresses influenza A virus myocarditis by increasing neutralizing antibody titers and the suppression of myocardial virus activities. From the standpoint of suppression of MIP-2 concentrations, intact type is superior to F(ab')2 type. Thus, immunoglobulin treatment may be promising for prevention of influenza virus myocarditis.
Similar articles
- [Effects of immunoglobulin on murine myocarditis caused by influenza A virus: experimental study].
Kishimoto C, Hiraoka Y, Takada H, Kurokawa M, Ochiai H. Kishimoto C, et al. J Cardiol. 2005 Jun;45(6):247-55. J Cardiol. 2005. PMID: 15991608 Japanese. - Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects.
Takada H, Kishimoto C, Hiraoka Y. Takada H, et al. Circulation. 1995 Sep 15;92(6):1604-11. doi: 10.1161/01.cir.92.6.1604. Circulation. 1995. PMID: 7664447 - Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.
Menachem A, Chapman J, Deri Y, Pick CG, Katzav A. Menachem A, et al. Clin Rev Allergy Immunol. 2013 Oct;45(2):248-55. doi: 10.1007/s12016-013-8357-z. Clin Rev Allergy Immunol. 2013. PMID: 23325332 Review. - Viral myocarditis.
Leonard EG. Leonard EG. Pediatr Infect Dis J. 2004 Jul;23(7):665-6. doi: 10.1097/01.inf.0000132280.36984.a9. Pediatr Infect Dis J. 2004. PMID: 15247607 Review. No abstract available.
Cited by
- A case of fulminant myocarditis associated with novel N1H1 influenza successfully treated by percutaneous cardiopulmonary support system.
Morimoto R, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Sasaki H, Niwa T, Izumi Y, Yamamoto T, Ichihashi K, Kanzaki Y, Nagai H, Iwata Y. Morimoto R, et al. J Cardiol Cases. 2010 Aug 6;2(2):e106-e110. doi: 10.1016/j.jccase.2010.05.004. eCollection 2010 Oct. J Cardiol Cases. 2010. PMID: 30524598 Free PMC article. - Intravenous immunoglobulin for the treatment of childhood encephalitis.
Iro MA, Martin NG, Absoud M, Pollard AJ. Iro MA, et al. Cochrane Database Syst Rev. 2017 Oct 2;10(10):CD011367. doi: 10.1002/14651858.CD011367.pub2. Cochrane Database Syst Rev. 2017. PMID: 28967695 Free PMC article. Review. - What Every Cardiologist Should Know about H1N1?
Golabchi A, Sarrafzadegan N. Golabchi A, et al. ARYA Atheroscler. 2010 Fall;6(3):118-21. ARYA Atheroscler. 2010. PMID: 22577427 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources